Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BouNDless trial of continuous subcutaneous ND0612 versus oral immediate-release levodopa/carbidopa in Parkinson's disease with motor fluctuations
2018-004156-37Phase 3Active
- Sponsor
- NeuroDerm Ltd.
- Start
- Sep 2019
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing ND0612 infusion arm with Oral immediate-release levodopa/carbidopa arm (2 arms). Primary endpoint: Change in ON time without troublesome dyskinesia. Started Sep 2019; status: active.
02
Drugs
ND0612levodopacarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2018-004156-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004156-37.